Vutrisiran is a small interfering RNA indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, among other approved uses. MedsAcross supplies Vutrisiran for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits
Source: US FDA prescribing information
Vutrisiran is a double-stranded siRNA-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.
Source: US FDA prescribing information
The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous injection once every 3 months. AMVUTTRA is for subcutaneous use only and should be administered by a healthcare professional.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Reduced serum vitamin A levels and recommended supplementation: Supplement with the recommended daily allowance of vitamin A. Refer to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.
Source: US FDA prescribing information
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Reduced Serum Vitamin A Levels and Recommended Supplementation The most common adverse reactions (≥5%) were pain in extremity, arthralgia, dyspnea, and vitamin A decreased.
Source: US FDA prescribing information
Store at 2°C to 30°C (36°F to 86°F) in the original carton, until ready for use. Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Vutrisiran, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Amvuttra 25 mg/0.5 mL injectionSubcutaneous | Alnylam Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Vutrisiran and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Vutrisiran, including Amvuttra.
Yes. The US FDA first approved Vutrisiran on 13 June 2022, according to Drugs@FDA.
Yes. Vutrisiran has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Vutrisiran is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Vutrisiran is classified under ATC code N07XX18 (Vutrisiran).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.